STING AND TLR-Targeted Therapies Summit 2023

Memo

The field of innate immune target-mediated activation has experienced a dynamic year, with both promising clinical data on the horizon and recent setbacks on the minds of drug developers. In light of these developments, it is an ideal time to bring together the community to discuss the current state of the industry and consider next steps. The 4th STING AND TLR Targeting Therapies Summit will bring together over 100 leading figures in the field of innate targeting therapies, representing large pharmaceutical companies, biotech firms, and academia. This event will provide a unique opportunity to explore the various STING AND TLR agonists in development, review clinical trial data, learn from high-profile failures, evaluate delivery approaches, and discuss strategies to optimize clinical trials and accelerate your innate agonist pipelines. Don't miss out on this chance to meet your first in person for the first time and get up to date on the latest research and developments in innate immune targeting therapies. URLs: Tickets: https://go.evvnt.com/1487132-2?pid=5569Brochure: https://go.evvnt.com/1487132-3?pid=5569 Date and Time: On Tue, May 9, 2023 ( 8:00 AM) - Thu, May 11, 2023 ( 4:30 PM) Venue details: Hilton Boston Back Bay, 40 Dalton Street, Boston, Massachusetts, 02115, United States Prices:Conference + Pre Conference Focus Day - Drug Developer: USD 4297.00,Conference Only - Drug Developer: USD 2999.00,Conference + Pre Conference Focus Day - Academic: USD 3697.00,Conference Only - Academic: USD 2599.00,Conference + Pre Conference Focus Day - Service Providers: USD 5297.00,Conference Only - Service Providers: USD 3799.00 Speakers: Mark Moody, Chief Operating Officer, Activate Therapeutics, Shou-Ching Jaminet, Vice President of Discovery Science, Angiex Inc, Suchul Jang Director, Preclinical and Biomarkers, Codiak Biosciences, Carman Giacomantonio, Professor of Surgery, Dalhousie University, Natalie Artzi, Assistant Professor, Harvard Medical School, Peter DeMuth, Chief Scientific Officer, Elicio Therapeutics, Lijun "Josh" Sun, Director, ImmuneSensor Therapeutics, Michelle Dion, PhD Candidate, Harvard-MIT Health Sciences and Technology, Pere Dosta Pons, Instructor in Medicine, Harvard Medical School, James Appleman, Senior Vice President and Chief Scientific Officer, Primmune Therapeutics, Inc., Kartik Krishnan, Chief Medical Officer, OncoNano Medicine Inc., Michael Newman, Chief Scientific Officer, Indaptus tx, Robert Andtbacka, Chief Medical Officer, 7 and 8 Biopharma, Travis Shaffer, Scientist, Regeneron Pharmaceuticals Inc, Yasu Hiro Nagai, Senior Research Scientist, Sumitomo Pharma Oncology, Lei Jin, Associate Professor of Medicine, University of Florida, Richard Gregory, Director - Global Translational Lead, Takeda Oncology, Thomas W. Dubensky, President, Tempest Therapeutics, Beacon Targeted Therapies, Graham Garnett, Scientist, Medicinal Chemistry, Zymeworks, Jinming Gao, Elaine Dewey Sammons Distinguished Chair in Cancer Research, UT Southwestern Medical Center